A Multicenter, Two-Part, Open-Label, Phase 1B Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy in Subjects With Advanced Melanoma

Trial Profile

A Multicenter, Two-Part, Open-Label, Phase 1B Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy in Subjects With Advanced Melanoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Aug 2017

At a glance

  • Drugs CMP 001 (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Sponsors Checkmate Pharmaceuticals
  • Most Recent Events

    • 02 Aug 2017 Planned number of patients changed from 60 to 160.
    • 10 Jun 2017 Biomarkers information updated
    • 14 Dec 2016 According to a Genocea media release, antigen identification screening system ATLAS will be used to profile the T cell responses in 20 patients enrolled in this trial to identify antigens associated with positive or negative patient outcomes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top